US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Custom Truck One Source Inc

3.76

-0.0400-1.05%

Post-market: 3.55-0.2100-5.59%16:33 EDT

Volume:2.51M

Turnover:9.39M

Market Cap:848.45M

PE:-31.10

High:3.81

Open:3.74

Low:3.51

Close:3.80

Loading ...

Overview Company News Filings

Immutep Quarterly Activities Report Q2 FY25

Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

Are Investors Undervaluing Custom Truck One Source (CTOS) Right Now?

Insider Stock Buying Reaches US$822.2k On Custom Truck One Source

Simply Wall St.

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

GSK Enters Agreement to Acquire IDRx, Inc.

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

D.A. Davidson Sticks to Their Buy Rating for Custom Truck One Source (CTOS)

Further weakness as Custom Truck One Source (NYSE:CTOS) drops 4.2% this week, taking three-year losses to 32%

Simply Wall St.

Returns On Capital At Custom Truck One Source (NYSE:CTOS) Have Hit The Brakes

Simply Wall St.

Custom Truck One Source's (NYSE:CTOS) Returns Have Hit A Wall

Simply Wall St.

Custom Truck One Source to Participate in the BofA Securities 2024 Leveraged Finance Conference

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

Reflecting On Specialty Equipment Distributors Stocks’ Q3 Earnings: Custom Truck One Source (NYSE:CTOS)

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS

CTOS Digital Malaysia 3rd-Quarter 2024 Earnings Summary Table

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

BRIEF-SpringWorks Therapeutics to Present Phase 3 DeFi Trial Data of Ogsiveo in Desmoid Tumors at CTOS 2024 Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CTOS/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTOS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTOS\",,,,,undefined,":{"symbol":"CTOS","market":"US","secType":"STK","nameCN":"Custom Truck One Source Inc","latestPrice":3.76,"timestamp":1745265600000,"preClose":3.8,"halted":0,"volume":2512119,"hourTrading":{"tag":"盘后","latestPrice":3.55,"preClose":3.76,"latestTime":"16:33 EDT","volume":983280,"amount":3697080.3905,"timestamp":1745267610915},"delay":0,"floatShares":58678113,"shares":225650684,"eps":-0.120919,"marketStatus":"Closed","change":-0.04,"latestTime":"04-21 16:00:00 EDT","open":3.74,"high":3.805,"low":3.505,"amount":9386042.780295001,"amplitude":0.078947,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.120919,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745308800000},"marketStatusCode":5,"adr":0,"exchange":"NYSE","adjPreClose":3.8,"postHourTrading":{"tag":"盘后","latestPrice":3.55,"preClose":3.76,"latestTime":"16:33 EDT","volume":983280,"amount":3697080.3905,"timestamp":1745267610915},"volumeRatio":1.999742,"impliedVol":0.6348,"impliedVolPercentile":0.116},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTOS\",,,,,undefined,":{"symbol":"CTOS","floatShares":58678113,"roa":"2.20%","roe":"-3.22%","lyrEps":-0.120919,"volumeRatio":1.999742,"shares":225650684,"dividePrice":0,"high":3.805,"amplitude":0.078947,"preClose":3.8,"low":3.505,"week52Low":3.03,"pbRate":"0.99","psRate":"0.47","week52High":6.11,"institutionHeld":0,"latestPrice":3.76,"eps":-0.120919,"divideRate":0,"volume":2512119,"delay":0,"ttmEps":-0.120919,"open":3.74,"prevYearClose":4.81,"prevWeekClose":3.8,"prevMonthClose":4.22,"prevQuarterClose":4.22,"fiveDayClose":3.41,"twentyDayClose":4.79,"sixtyDayClose":5.37,"earningDate":1745942400000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTOS\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2507957164","title":"Immutep Quarterly Activities Report Q2 FY25","url":"https://stock-news.laohu8.com/highlight/detail?id=2507957164","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507957164?lang=en_us&edition=fundamental","pubTime":"2025-01-31 21:00","pubTimestamp":1738328400,"startTime":"0","endTime":"0","summary":"Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer  received first regulatory approval. Mature data from INSIGHT-003 in 1L NSCLC demonstrates an excellent 32.9-month median overall survival  and 81.0% 24-month OS rate, significantly outperforming historical controls. Promising new results in first line head & neck cancer with PD-L1 CPS <1 reported at ESMO IO 2024, with median OS not reached and 67% 12-month OS rate well above historical controls. Phase II in soft tissue sarcoma shows three-fold increase in tumour hyalinization  compared to historical data from radiotherapy. Phase I trial of IMP761 reported favourable initial safety results advancing the first-in-class agonist LAG-3 antibody program. TACTI-004 – Start of Phase III Trial in 1L NSCLCIn December 2024, Immutep initiated its pivotal TACTI-004 Phase III clinical trial of eftilagimod alfa  for the treatment of first-line metastatic non-small cell ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-quarterly-activities-report-q2-130000670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","ORR","INAQU","BK4139","BK4563","PFS","CTOS","IMM.AU","BK4097","BK4179","BK4195","IO","IMMP","BK4211","BK4104"],"gpt_icon":0},{"id":"2505744498","title":"Patient Enrolment Completed for EFTISARC-NEO Phase II Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2505744498","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505744498?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550800,"startTime":"0","endTime":"0","summary":"Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA  in patients with soft tissue sarcoma reaches enrolment target of 40 patients. SYDNEY, AUSTRALIA, Jan. 22, 2025  -- Immutep Limited  , a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that patient enrolment has been completed in the investigator-initiated EFTISARC-NEO trial. EFTISARC-NEO is evaluating eftilagimod alpha  in combination with radiotherapy plus KEYTRUDA  in the neoadjuvant setting for patients with resectable soft tissue sarcoma .Additionally, the treatment has been safe with no grade ≥3 toxicities related to efti and pembrolizumab.About ImmutepImmutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 , and our diversified product portfolio harness","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/patient-enrolment-completed-eftisarc-neo-130000186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0006306889.USD","LU1430594728.SGD","LU0211331839.USD","IMMP","LU0861579265.USD","LU2023250504.SGD","LU1037948541.HKD","LU1037948897.HKD","BK4588","IE00BSNM7G36.USD","LU1066051811.HKD","LU0289739699.SGD","LU0965509101.SGD","IE00BLSP4452.SGD","BK4533","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0265550359.USD","LU2112291526.USD","BK4104","LU0203347892.USD","BK4585","IE00BLSP4239.USD","IE00BN8TJ469.HKD","LU1571399168.USD","LU2361044865.SGD","MRK","LU1989771016.USD","LU1291159041.SGD","BK4196","BK4534","NEO","CTOS","BK4007","BK4516","LU2461242641.AUD","SG9999001176.SGD","LU0012050646.USD","LU0106261372.USD","LU1116320901.HKD","LU2324357040.USD","LU2468319806.SGD","BK4559","SGXZ57979304.SGD","LU0265550946.USD","LU0320765489.SGD","SG9999001440.SGD","LU1093756168.USD","LU1162221912.USD"],"gpt_icon":0},{"id":"2505238253","title":"Are Investors Undervaluing Custom Truck One Source (CTOS) Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2505238253","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505238253?lang=en_us&edition=fundamental","pubTime":"2025-01-20 22:40","pubTimestamp":1737384017,"startTime":"0","endTime":"0","summary":"Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.One stock to keep an eye on is Custom Truck One Source . CTOS is currently sporting a Zacks Rank of #2 , as well as a Value grade of A.Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price with the company's sales. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investors-undervaluing-custom-truck-one-144017823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","BK4104","ISBC","CTOS"],"gpt_icon":0},{"id":"2504103095","title":"Insider Stock Buying Reaches US$822.2k On Custom Truck One Source","url":"https://stock-news.laohu8.com/highlight/detail?id=2504103095","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504103095?lang=en_us&edition=fundamental","pubTime":"2025-01-18 20:51","pubTimestamp":1737204691,"startTime":"0","endTime":"0","summary":"It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in Custom Truck One Source, Inc.'s  case, it's fantastic news for shareholders.While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.View our latest analysis for Custom Truck One Source. Custom Truck One Source Insider Transactions Over The Last Year. Over the last year, we can see that the biggest insider purchase was by President of Sales Joseph Ross for US$335k worth of shares, at about US$3.98 per share. We do like to see buying, but this purchase was made at well below the current price of US$4.76. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.Get in touch with us directly. Alternatively, email editorial-team (a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insider-stock-buying-reaches-us-125131253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4104","CTOS"],"gpt_icon":0},{"id":"2503430141","title":"Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503430141","media":"Newsfile","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503430141?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773200,"startTime":"0","endTime":"0","summary":"The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets. Adaptimmune Allo-T program to be featured at the Biotech ShowCase and the Wuxi Global Forum 2025. More details about the Company's sarcoma franchise, including the lete-cel clinical program and launch progress for TECELRA , the Company's first commercial product and the first FDA approved engineered cell therapy for a solid tumor, will be provided during the Company's presentation at the Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, California, on Tuesday, January 14th, 2025, 4:30-5:10 PM PST .Adrian Rawcliffe, Adaptimmune's Chief Executive Office: \"This designation by the FDA highlights the potential of lete-cel to address a critical need for new treatment options for patients with MRCLS. This is another important milestone in building out our sarcoma franchise, as we aim to bring lete-cel to ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/adaptimmune-announces-u-fda-breakthrough-130000177.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adaptimmune-announces-u-fda-breakthrough-130000177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0031619046.USD","IE00B7SZL793.SGD","TM","BK4585","BK4139","LU2065731478.USD","03160","BK4006","ADAP","IE00B19Z4B17.USD","BK4588","CTOS","BK4099","IE00B66KJ199.SGD","BK4555","BK4104","CRS"],"gpt_icon":0},{"id":"2503326913","title":"GSK Enters Agreement to Acquire IDRx, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2503326913","media":"Business Wire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503326913?lang=en_us&edition=fundamental","pubTime":"2025-01-13 15:05","pubTimestamp":1736751900,"startTime":"0","endTime":"0","summary":"Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor  designed to treat gastrointestinal stromal tumours . IDRX-42 offers potential to address all key KIT mutations in GIST that drive tumour growth and progression and improve tolerability, gaps in current therapies. Acquisition adds to GSK’s growing portfolio in gastrointestinal  cancers. Tony Wood, Chief Scientific Officer, GSK, said: \"We are excited by the early data from IDRX-42 and its unique ability to target all clinically relevant KIT mutations present in GIST, a major gap in the current standard of care. We look forward to accelerating its development in 2025 to redefine treatment.\". Updated clinical data from StrateGIST 1, an ongoing phase I/Ib trial of IDRX-42 in patients with advanced GIST, were presented in an oral presentation at the Connective Tissue Oncology Society  2024 Annual Meeting. These data show promising anti-tumour activity of IDRX-42 in patients with advanced GIST with a manageable sa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gsk-enters-agreement-acquire-idrx-070500791.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LU1829250122.USD","BK4585","BK4161","MMAT","GSK","GSK.UK","BK4141","BK4532","BK4104","CTOS","BK4588","CR"],"gpt_icon":0},{"id":"2502667865","title":"Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6","url":"https://stock-news.laohu8.com/highlight/detail?id=2502667865","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502667865?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:00","pubTimestamp":1736514000,"startTime":"0","endTime":"0","summary":"The US FDA, Health Canada, European Medicines Authority, and the Australian Therapeutic Goods Administration authorized the Company's global, randomized Phase 3 study  in Metastatic Soft Tissue Sarcoma. Twenty-three sites are currently contracted in the INVINCIBLE 3 study, and several sites have treated patients. Seven Swiss sites are activated in the Phase 2  study for early-stage, operable Triple Negative Breast Cancer , and several patients have been treated. SHELTON, Conn., Jan. 10, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. , a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announces a business update highlighting key achievements with its lead drug candidate INT230-6.In October 2024, the Company, in collaboration with the Swiss Group for Clinical Cancer Research SAKK  in the INVINCIBLE-4 Study,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/intensity-therapeutics-provides-business-highlighting-130000009.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/intensity-therapeutics-provides-business-highlighting-130000009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4213","BK4131","INTS","CTOS","LU0061475181.USD","LU0149725797.USD","BK4534","LU0070302665.USD","UPS","LU1585245621.USD","LU2237438978.USD","IE0002270589.USD","BK4532","IE00BFSS7M15.SGD","LU1162221912.USD","LU0208291251.USD","PR","BK4559","IE00B19Z3B42.SGD","LENZ","LU2133065610.SGD","IE0004445015.USD","BK4588","IE00B19Z3581.USD","LU0211331839.USD","BK4104","IE00BFSS8Q28.SGD","IE00B7SZLL34.SGD","BK4585","LU0320765489.SGD","IE00BJJMRX11.SGD","BK4139","LU0320765646.SGD","BK4550","IE00BJJMRY28.SGD","LU1074936037.SGD","LU1430594728.SGD","IE00B7KXQ091.USD"],"gpt_icon":0},{"id":"2493769937","title":"D.A. Davidson Sticks to Their Buy Rating for Custom Truck One Source (CTOS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2493769937","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493769937?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:45","pubTimestamp":1734965113,"startTime":"0","endTime":"0","summary":"D.A. Davidson analyst Michael Shlisky maintained a Buy rating on Custom Truck One Source (CTOS – Research Report) today. The company’s shares opene...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/d-a-davidson-sticks-to-their-buy-rating-for-custom-truck-one-source-ctos-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/d-a-davidson-sticks-to-their-buy-rating-for-custom-truck-one-source-ctos-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTOS"],"gpt_icon":0},{"id":"2492152716","title":"Further weakness as Custom Truck One Source (NYSE:CTOS) drops 4.2% this week, taking three-year losses to 32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492152716","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492152716?lang=en_us&edition=fundamental","pubTime":"2024-12-18 23:27","pubTimestamp":1734535621,"startTime":"0","endTime":"0","summary":"It is a pleasure to report that the Custom Truck One Source, Inc. ( NYSE:CTOS ) is up 35% in the last quarter. But that...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/3081000-choice2-main-header/1585186749644","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3081000-choice2-main-header/1585186749644"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-ctos/custom-truck-one-source/news/further-weakness-as-custom-truck-one-source-nysectos-drops-4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NYSE","CTOS","BK4104"],"gpt_icon":0},{"id":"2487572570","title":"Returns On Capital At Custom Truck One Source (NYSE:CTOS) Have Hit The Brakes","url":"https://stock-news.laohu8.com/highlight/detail?id=2487572570","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487572570?lang=en_us&edition=fundamental","pubTime":"2024-11-30 21:45","pubTimestamp":1732974327,"startTime":"0","endTime":"0","summary":"If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for?In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. Although, when we looked at Custom Truck One Source , it didn't seem to tick all of these boxes.For those who don't know, ROCE is a measure of a company's yearly pre-tax profit , relative to the capital employed in the business. Analysts use this formula to calculate it for Custom Truck One Source:. Return on Capital Employed = Earnings Before Interest and Tax  ÷ . In summary, Custom Truck One Source has simply been reinvesting capital and generating the same low rate of return as before. Although the market must be expecting these trends to improve because the stock","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/DSVnwZKEypugE5XiS5bHWw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/7d457e118489e6e5357eb5fd232e46f8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/DSVnwZKEypugE5XiS5bHWw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/7d457e118489e6e5357eb5fd232e46f8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/returns-capital-custom-truck-one-134527248.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTOS","BK4104","EBIT","NYSE"],"gpt_icon":0},{"id":"2486386708","title":"Custom Truck One Source's (NYSE:CTOS) Returns Have Hit A Wall","url":"https://stock-news.laohu8.com/highlight/detail?id=2486386708","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486386708?lang=en_us&edition=fundamental","pubTime":"2024-11-27 22:22","pubTimestamp":1732717355,"startTime":"0","endTime":"0","summary":"What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/3081000-choice2-main-header/1585186749644","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3081000-choice2-main-header/1585186749644"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-ctos/custom-truck-one-source/news/custom-truck-one-sources-nysectos-returns-have-hit-a-wall","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4104","CTOS","NYSE","EBIT"],"gpt_icon":0},{"id":"2485232474","title":"Custom Truck One Source to Participate in the BofA Securities 2024 Leveraged Finance Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2485232474","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485232474?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:10","pubTimestamp":1732223400,"startTime":"0","endTime":"0","summary":"KANSAS CITY, Mo., November 21, 2024----Custom Truck One Source, Inc.  today announced that President and Chief Executive Officer, Ryan McMonagle, and Chief Financial Officer, Chris Eperjesy, will participate in a fireside chat and meet with institutional investors at the BofA Securities 2024 Leveraged Finance Conference in Boca Raton, FL on Tuesday, December 3, 2024. The fireside chat is scheduled to begin at 8:10 a.m. ET.ABOUT CUSTOM TRUCK ONE SOURCECustom Truck One Source is one of the largest providers of specialty equipment, parts, tools, accessories and services to the electric utility transmission and distribution, telecommunications, and rail markets in North America, with a differentiated \"one-stop-shop\" business model. The Company offers its specialized equipment to a diverse customer base for the maintenance, repair, upgrade, and installation of critical infrastructure assets, including electric lines, telecommunications networks, and rail systems. The Company's coast-to-coas","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/JiTlZ7Fn29yV5bUozrpJqg--~B/aD01NjI7dz0xNjA0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/3a241e98edc1c3ff08b027123f2b3570","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/JiTlZ7Fn29yV5bUozrpJqg--~B/aD01NjI7dz0xNjA0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/3a241e98edc1c3ff08b027123f2b3570"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/custom-truck-one-source-participate-211000794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTOS","BK4104"],"gpt_icon":0},{"id":"2484622654","title":"Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial (\"INVINCIBLE-3 Study\") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2484622654","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484622654?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:00","pubTimestamp":1731934800,"startTime":"0","endTime":"0","summary":"Phase 1/2 data showed a median overall survival  of 21.3 months versus a synthetic control of 6.7 months, an increase in T-cell activation, and favorable safety profile for patients receiving INT230-6 alone. INVINCIBLE-3 Study is recruiting and expected to enroll 333 patients with leiomyosarcoma, liposarcoma and undeferential pleomorphic sarcoma; authorizations for the INVINCIBLE-3 Study have been received in the U.S., Canada, Europe and Australia. \"The data in the Phase 1/2 study has shown that INT230-6 causes cell death leading to tumor necrosis, improved cancer recognition by immune cells, and an ignition of a systemic anti-cancer immune response that results in T-cells enteringthe tumor microenvironment and has shown a favorable safety profile in soft tissue sarcomas,\" said Dr. Razak. \"Systemically delivered chemotherapies have severe side effects, including cardiotoxicity, and most sarcoma subtypes have only a minimal response to immunotherapies. In addition, most sarcoma patients","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QlyJbPGPoLtUoNB9aBdoWw--~B/aD0xMDE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/05963c77aa494c20fbf5e997876cf9c8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QlyJbPGPoLtUoNB9aBdoWw--~B/aD0xMDE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/05963c77aa494c20fbf5e997876cf9c8"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/intensity-therapeutics-presents-int230-6-130000048.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/intensity-therapeutics-presents-int230-6-130000048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU0154245673.USD","LU2517655291.USD","LU1814569148.SGD","BK4588","INTS","BK4134","LU0107464264.USD","LU0154245756.USD","BK4585","LENZ","BK4213","CTOS","LU2517655028.SGD","IT","LU2517655374.HKD","SD","BK4104"],"gpt_icon":0},{"id":"2483787758","title":"Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2483787758","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483787758?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589200,"startTime":"0","endTime":"0","summary":"Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients with soft tissue sarcoma. Over three-fold increase in tumour hyalinization, the primary endpoint of the study and an important predictor of overall survival, as compared to historical results from radiotherapy alone. SYDNEY, AUSTRALIA, Nov. 14, 2024  -- Immutep Limited  , a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha  in combination with radiotherapy plus KEYTRUDA  for patients with soft tissue sarcoma , at the Connective Tissue Oncology Society  2024 Annual Meeting. Based on preliminary analysis among 21 patients available for primary endpoint assessment, the triple combination therapy demonstrates significant efficacy in the neoadjuvant setting for resectable STS.Dr. F","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rMGJzQlu_.sxjdfFCHAlRg--~B/aD0xMDM7dz0yNDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/caf92fc65a13b56708c85c7546e3ac3d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rMGJzQlu_.sxjdfFCHAlRg--~B/aD0xMDM7dz0yNDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/caf92fc65a13b56708c85c7546e3ac3d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/positive-data-phase-ii-trial-130000666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4139","IMM.AU","BK7067","BK4104","CTOS","BK7508","IMMP"],"gpt_icon":1},{"id":"2483338057","title":"Reflecting On Specialty Equipment Distributors Stocks’ Q3 Earnings: Custom Truck One Source (NYSE:CTOS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483338057","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483338057?lang=en_us&edition=fundamental","pubTime":"2024-11-14 18:23","pubTimestamp":1731579788,"startTime":"0","endTime":"0","summary":"Wrapping up Q3 earnings, we look at the numbers and key takeaways for the specialty equipment distributors stocks, including Custom Truck One Source  and its peers.Historically, specialty equipment distributors have boasted deep selection and expertise in sometimes narrow areas like single-use packaging or unique lighting equipment. Additionally, the industry has evolved to include more automated industrial equipment and machinery over the last decade, driving efficiencies and enabling valuable data collection. Specialty equipment distributors whose offerings keep up with these trends can take share in a still-fragmented market, but like the broader industrials sector, this space is at the whim of economic cycles that impact the capital spending and manufacturing propelling industry volumes.The 9 specialty equipment distributors stocks we track reported a slower Q3. As a group, revenues were in line with analysts’ consensus estimates.Thankfully, share prices of the companies have been ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/AncmcXXrlwVqhYCxb0O6qw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/e31da72fb1536446dbeecbeab5112387","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/AncmcXXrlwVqhYCxb0O6qw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/e31da72fb1536446dbeecbeab5112387"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/reflecting-specialty-equipment-distributors-stocks-102308844.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTOS","NYSE","RELL"],"gpt_icon":0},{"id":"2483886729","title":"Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2483886729","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483886729?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:00","pubTimestamp":1731506400,"startTime":"0","endTime":"0","summary":"42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-cel. Results include six complete responses ; twenty-one partial responses . Data to be presented at Connective Tissue Oncology Society 2024 Annual Meeting. Company plans to initiate a rolling BLA submission for lete-cel for the treatment of advanced or metastatic synovial sarcoma and MRCLS by end of 2025. Elliot Norry, MD, Adaptimmune's Chief Medical Officer: \"We are thrilled to see that 42% of patients with synovial sarcoma or MRCLS responded to treatment with lete-cel, following prior treatment with currently available therapies. Responses were durable across both indications, with an overall median duration of response greater than 18 months for people with synovial sarcoma and greater than one year for MRCLS. These data underscore lete-cel's potential to transform the lives of people with these cancers who have a poor prognosis and few treatment options. We look forward to presenti","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1SU3IzwwL2pQV2XN87zEaA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/bc15e0ba6fbc6013498fb1ebca3d5782","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1SU3IzwwL2pQV2XN87zEaA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/bc15e0ba6fbc6013498fb1ebca3d5782"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/adaptimmunes-lete-cel-achieves-primary-140000462.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adaptimmunes-lete-cel-achieves-primary-140000462.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z4B17.USD","CTOS","IE00B66KJ199.SGD","IE00B7SZL793.SGD","ADAP","BK4139","BK4006","IE0031619046.USD","BK4195","BK4104","PFS","BK4211","CRS"],"gpt_icon":1},{"id":"2483755002","title":"Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS","url":"https://stock-news.laohu8.com/highlight/detail?id=2483755002","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483755002?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:00","pubTimestamp":1731502800,"startTime":"0","endTime":"0","summary":"BASKING RIDGE, N.J., November 13, 2024----Daiichi Sankyo  will highlight new clinical research and real-world data from seven abstracts for TURALIO  at the Connective Tissue Oncology Society  2024 Annual Meeting.TURALIO is the first and only oral systemic therapy approved in the U.S. for adult patients with tenosynovial giant cell tumor  associated with severe morbidity or functional limitations and not amenable to improvement with surgery. TGCT is a rare and typically non-malignant tumor that affects small and large joints.1,2,3. \"These latest data being presented at CTOS continue to support the role of TURALIO as a treatment option for certain patients with tenosynovial giant cell tumor,\" said Dan Switzer, Head of U.S. Oncology Business, Daiichi Sankyo, Inc. \"As a leader in TGCT research and development, Daiichi Sankyo has made significant progress in transforming the treatment landscape for patients with this rare, debilitating tumor and we remain committed to educating the medical ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Q_Ud.j.faz9TGQm1x1aHQg--~B/aD0yODA7dz0yNjc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0eaf3e57716fb77929dd27bf6662f931","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Q_Ud.j.faz9TGQm1x1aHQg--~B/aD0yODA7dz0yNjc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0eaf3e57716fb77929dd27bf6662f931"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/daiichi-sankyo-showcase-turalio-research-130000028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4104","BK4139","DSKYF","CTOS","ALT","AST","BK4007","LU1878469433.USD","GGT","DSNKY","PST"],"gpt_icon":0},{"id":"2482227051","title":"CTOS Digital Malaysia 3rd-Quarter 2024 Earnings Summary Table","url":"https://stock-news.laohu8.com/highlight/detail?id=2482227051","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482227051?lang=en_us&edition=fundamental","pubTime":"2024-11-11 17:14","pubTimestamp":1731316440,"startTime":"0","endTime":"0","summary":"CTOS Digital  - Malaysia  quarter ended Sep 30: Figures Are In Ringgit . 20242023 Revenue79,809,00066,451,000 PreTax Profit29,783,00030,417,000 Net Profit27,553,00024,386,000 Earnings Per Share1.20 Sen1.10 Sen Dividend0.84 Sen0.64 Sen 9 months ended Sep 30: Revenue228,031,000188,287,000 PreTax Profit79,201,00078,437,000 Net Profit73,876,00062,095,000 Earnings Per Share3.20 Sen2.70 Sen Dividend2.26 Sen1.62 Sen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOS"],"gpt_icon":0},{"id":"2481817077","title":"Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2481817077","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481817077?lang=en_us&edition=fundamental","pubTime":"2024-11-08 21:01","pubTimestamp":1731070860,"startTime":"0","endTime":"0","summary":"SHELTON, Conn., Nov. 8, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ,  a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumorally injected cancer therapies intended to kill tumors directly and increase immune system recognition of cancers,today announced that its Phase 3 trial has been selected for an oral podium presentation at the 2024 Connective Tissue Oncology Society  on November 16, 2024. Dr. Christian F. Meyer MD, Ph.D will be making the oral presentation highlighting completed Phase 2 results and the INVINCIBLE-3  randomized soft tissue sarcoma trial design and important study criteria. The annual CTOS conference runs from November 13 to 16, 2024 in San Diego at the Grand Hyatt.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QlyJbPGPoLtUoNB9aBdoWw--~B/aD0xMDE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/05963c77aa494c20fbf5e997876cf9c8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QlyJbPGPoLtUoNB9aBdoWw--~B/aD0xMDE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/05963c77aa494c20fbf5e997876cf9c8"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/intensity-therapeutics-selected-oral-podium-130100146.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/intensity-therapeutics-selected-oral-podium-130100146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTOS","LENZ","BK4104","INTS","BK4139"],"gpt_icon":0},{"id":"2481314904","title":"BRIEF-SpringWorks Therapeutics to Present Phase 3 DeFi Trial Data of Ogsiveo in Desmoid Tumors at CTOS 2024 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2481314904","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481314904?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:07","pubTimestamp":1730984871,"startTime":"0","endTime":"0","summary":"Nov 7  - SpringWorks Therapeutics Inc   :   * SPRINGWORKS THERAPEUTICS ANNOUNCES LONG-TERM EFFICACY AND SAFETY DATA FROM PHASE 3 DEFI TRIAL OF OGSIVEO  IN ADULTS WITH DESMOID TUMORS TO BE PRESENTED AT THE CONNECTIVE TISSUE ONCOLOGY SOCIETY  2024 ANNUAL MEETING   * SPRINGWORKS THERAPEUTICS INC - NIROGACESTAT SHOWS FURTHER TUMOR SIZE REDUCTIONS AND INCREASED ORR   * SPRINGWORKS THERAPEUTICS INC - MEDIAN TUMOR SIZE REDUCTION OF 75.8% AFTER FOUR YEARS OF NIROGACESTATSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","LENZ","SWTX","CTOS","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":77,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTOS\",params:#limit:5,,,undefined,":[{"date":"2025-04-30","symbol":"CTOS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.07,"defaultRemindTime":1746043200000,"name":null,"time":"Post Market","dateTimestamp":1745985600000,"actualEps":null},{"market":"US","date":"2025-03-04","symbol":"CTOS","fiscalQuarterEnding":"2024/12","expectedEps":0.04,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741064400000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2024-10-30","symbol":"CTOS","fiscalQuarterEnding":"2024/09","expectedEps":-0.03,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730260800000,"reportTimeType":"post","actualEps":-0.07},{"market":"US","date":"2024-08-01","symbol":"CTOS","fiscalQuarterEnding":"2024/06","expectedEps":-0.01,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722484800000,"reportTimeType":"post","actualEps":-0.1},{"market":"US","date":"2024-05-02","symbol":"CTOS","fiscalQuarterEnding":"2024/03","expectedEps":-0.01,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1714622400000,"reportTimeType":"post","actualEps":-0.06}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTOS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTOS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.3333,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":6,"updateTime":1718510400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CTOS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CTOS","date":"2025-04-17","current":-26.69537,"percent":0.307317,"low":-132.987925,"twenty":-36.909507,"median":-9.553231,"eighty":29.102315,"high":435.227697,"avg":11.88451,"sd":111.786545,"marketCap":764955818},"quantilePoints":[{"date":"2020-04-24","current":-4.531449,"twenty":-15.350187,"median":-6.355137,"eighty":-4.975999,"marketCap":122584757},{"date":"2020-05-01","current":-4.241436,"twenty":-15.278791,"median":-6.311309,"eighty":-4.850398,"marketCap":114739333},{"date":"2020-05-08","current":-3.431306,"twenty":-15.253292,"median":-6.223652,"eighty":-4.748091,"marketCap":124546113},{"date":"2020-05-15","current":-2.78287,"twenty":-15.064602,"median":-6.165214,"eighty":-4.702252,"marketCap":101009840},{"date":"2020-05-22","current":-3.728506,"twenty":-14.712721,"median":-6.004509,"eighty":-4.618512,"marketCap":135333572},{"date":"2020-05-29","current":-3.350252,"twenty":-14.437335,"median":-5.9899,"eighty":-4.531449,"marketCap":121604079},{"date":"2020-06-05","current":-4.120269,"twenty":-14.289443,"median":-5.924157,"eighty":-4.435447,"marketCap":149553404},{"date":"2020-06-12","current":-4.68765,"twenty":-14.248645,"median":-5.887633,"eighty":-4.422694,"marketCap":170147643},{"date":"2020-06-19","current":-5.700831,"twenty":-14.16705,"median":-5.829195,"eighty":-4.425087,"marketCap":206923070},{"date":"2020-06-26","current":-6.295231,"twenty":-14.110953,"median":-5.873024,"eighty":-4.426682,"marketCap":228497987},{"date":"2020-07-02","current":-5.228013,"twenty":-14.080354,"median":-5.843805,"eighty":-4.432526,"marketCap":189761204},{"date":"2020-07-10","current":-5.106432,"twenty":-13.947761,"median":-5.814585,"eighty":-4.447135,"marketCap":185348153},{"date":"2020-07-17","current":-5.71434,"twenty":-13.78457,"median":-5.770757,"eighty":-4.473432,"marketCap":207413409},{"date":"2020-07-24","current":-4.930814,"twenty":-13.769271,"median":-5.727939,"eighty":-4.512417,"marketCap":178973745},{"date":"2020-07-31","current":-4.53905,"twenty":-13.759071,"median":-5.700831,"eighty":-4.531449,"marketCap":164753914},{"date":"2020-08-07","current":-3.77578,"twenty":-13.743772,"median":-5.6831,"eighty":-4.512417,"marketCap":166224931},{"date":"2020-08-14","current":-4.321542,"twenty":-13.713174,"median":-5.653881,"eighty":-4.426682,"marketCap":190251543},{"date":"2020-08-21","current":-4.187886,"twenty":-13.636678,"median":-5.631966,"eighty":-4.407205,"marketCap":184367475},{"date":"2020-08-28","current":-4.477473,"twenty":-13.560182,"median":-5.566224,"eighty":-4.382853,"marketCap":197116290},{"date":"2020-09-04","current":-4.499749,"twenty":-13.504085,"median":-5.495135,"eighty":-4.385059,"marketCap":198096968},{"date":"2020-09-11","current":-4.588853,"twenty":-13.478586,"median":-5.41078,"eighty":-4.391487,"marketCap":202019680},{"date":"2020-09-18","current":-4.733647,"twenty":-13.40209,"median":-5.365236,"eighty":-4.405582,"marketCap":208394087},{"date":"2020-09-25","current":-4.510887,"twenty":-13.259298,"median":-5.34284,"eighty":-4.414196,"marketCap":198587307},{"date":"2020-10-02","current":-4.599991,"twenty":-13.238899,"median":-5.332472,"eighty":-4.422694,"marketCap":202510019},{"date":"2020-10-09","current":-4.845027,"twenty":-13.050209,"median":-5.28205,"eighty":-4.423492,"marketCap":213297478},{"date":"2020-10-16","current":-4.989821,"twenty":-12.621831,"median":-5.256481,"eighty":-4.426682,"marketCap":219671885},{"date":"2020-10-23","current":-5.056649,"twenty":-12.596332,"median":-5.215058,"eighty":-4.42793,"marketCap":222613919},{"date":"2020-10-30","current":-4.622267,"twenty":-12.45354,"median":-5.187486,"eighty":-4.434595,"marketCap":203490697},{"date":"2020-11-06","current":-4.444059,"twenty":-12.285249,"median":-5.16881,"eighty":-4.441845,"marketCap":195645272},{"date":"2020-11-13","current":-20.443985,"twenty":-13.050209,"median":-5.187486,"eighty":-4.446287,"marketCap":221633241},{"date":"2020-11-20","current":-19.946454,"twenty":-13.478586,"median":-5.215058,"eighty":-4.455338,"marketCap":216239512},{"date":"2020-11-27","current":-20.986746,"twenty":-13.667276,"median":-5.256481,"eighty":-4.455901,"marketCap":227517309},{"date":"2020-12-04","current":-30.334718,"twenty":-13.769271,"median":-5.268541,"eighty":-4.466335,"marketCap":328858677},{"date":"2020-12-11","current":-27.840832,"twenty":-14.126252,"median":-5.332472,"eighty":-4.477473,"marketCap":301822463},{"date":"2020-12-18","current":-27.886176,"twenty":-14.636225,"median":-5.336086,"eighty":-4.477473,"marketCap":302314030},{"date":"2020-12-24","current":-32.828604,"twenty":-15.278791,"median":-5.363104,"eighty":-4.486383,"marketCap":355894891},{"date":"2020-12-31","current":-33.418067,"twenty":-15.691869,"median":-5.365236,"eighty":-4.495282,"marketCap":362285269},{"date":"2021-01-08","current":-33.418067,"twenty":-16.227341,"median":-5.454608,"eighty":-4.499741,"marketCap":362285269},{"date":"2021-01-15","current":-33.327381,"twenty":-16.722014,"median":-5.537005,"eighty":-4.499749,"marketCap":361302134},{"date":"2021-01-22","current":-34.733025,"twenty":-17.135092,"median":-5.592759,"eighty":-4.504204,"marketCap":376540727},{"date":"2021-01-29","current":-34.551652,"twenty":-17.318683,"median":-5.639271,"eighty":-4.510887,"marketCap":374574457},{"date":"2021-02-05","current":-35.639893,"twenty":-17.492074,"median":-5.653881,"eighty":-4.515342,"marketCap":386372078},{"date":"2021-02-12","current":-37.635001,"twenty":-17.787858,"median":-5.690404,"eighty":-4.525795,"marketCap":408001049},{"date":"2021-02-19","current":-38.133778,"twenty":-18.246834,"median":-5.706575,"eighty":-4.531449,"marketCap":413408292},{"date":"2021-02-26","current":-36.728134,"twenty":-19.27705,"median":-5.741538,"eighty":-4.531449,"marketCap":398169699},{"date":"2021-03-05","current":-37.045537,"twenty":-19.694454,"median":-5.785367,"eighty":-4.532969,"marketCap":401610672},{"date":"2021-03-12","current":-20.446363,"twenty":-19.699299,"median":-5.814585,"eighty":-4.5401,"marketCap":435037264},{"date":"2021-03-19","current":-20.931531,"twenty":-20.013695,"median":-5.867982,"eighty":-4.544301,"marketCap":445360182},{"date":"2021-03-26","current":-21.000841,"twenty":-20.385173,"median":-5.902243,"eighty":-4.546529,"marketCap":446834884},{"date":"2021-04-01","current":-21.601525,"twenty":-20.446363,"median":-5.931462,"eighty":-4.555439,"marketCap":459615640},{"date":"2021-04-09","current":-113.008368,"twenty":-20.746705,"median":-5.9899,"eighty":-4.555439,"marketCap":2404479044},{"date":"2021-04-16","current":-115.781579,"twenty":-20.931531,"median":-6.004509,"eighty":-4.555439,"marketCap":2463484665},{"date":"2021-04-23","current":-112.315065,"twenty":-21.031976,"median":-6.042898,"eighty":-4.566577,"marketCap":2389727639},{"date":"2021-04-30","current":-118.554791,"twenty":-21.278079,"median":-6.173649,"eighty":-4.566577,"marketCap":2522490285},{"date":"2021-05-07","current":-123.554928,"twenty":-22.45516,"median":-6.201738,"eighty":-4.567701,"marketCap":2628878204},{"date":"2021-05-14","current":-70.85499,"twenty":-27.931519,"median":-6.28209,"eighty":-4.577715,"marketCap":2353448495},{"date":"2021-05-21","current":-71.012339,"twenty":-28.520983,"median":-6.342278,"eighty":-4.577715,"marketCap":2358674833},{"date":"2021-05-28","current":-78.647277,"twenty":-29.110447,"median":-6.384356,"eighty":-4.588853,"marketCap":2612269309},{"date":"2021-06-04","current":-80.352166,"twenty":-32.16659,"median":-6.413575,"eighty":-4.588853,"marketCap":2668897202},{"date":"2021-06-11","current":-71.080873,"twenty":-32.756054,"median":-6.515842,"eighty":-4.59224,"marketCap":2360951183},{"date":"2021-06-18","current":-66.995765,"twenty":-33.109733,"median":-6.545061,"eighty":-4.593087,"marketCap":2225264334},{"date":"2021-06-25","current":-69.818203,"twenty":-33.454342,"median":-6.691156,"eighty":-4.59861,"marketCap":2319011612},{"date":"2021-07-02","current":-70.635225,"twenty":-33.980325,"median":-6.764204,"eighty":-4.605275,"marketCap":2346148982},{"date":"2021-07-09","current":-65.80737,"twenty":-34.524446,"median":-7.063699,"eighty":-4.615999,"marketCap":2185791796},{"date":"2021-07-16","current":-60.905241,"twenty":-35.503863,"median":-7.407022,"eighty":-4.622267,"marketCap":2022967576},{"date":"2021-07-23","current":-60.830966,"twenty":-36.129601,"median":-7.523898,"eighty":-4.622267,"marketCap":2020500542},{"date":"2021-07-30","current":-57.859979,"twenty":-36.673722,"median":-11.844122,"eighty":-4.627636,"marketCap":1921819197},{"date":"2021-08-06","current":-56.820133,"twenty":-36.909507,"median":-12.111859,"eighty":-4.639212,"marketCap":1887280726},{"date":"2021-08-13","current":-11.639988,"twenty":-37.045537,"median":-12.226602,"eighty":-4.645312,"marketCap":1739258709},{"date":"2021-08-20","current":-11.602475,"twenty":-36.963919,"median":-11.856872,"eighty":-4.653328,"marketCap":1733653478},{"date":"2021-08-27","current":-14.230387,"twenty":-36.909507,"median":-12.226602,"eighty":-4.659592,"marketCap":2126318582},{"date":"2021-09-03","current":-14.841913,"twenty":-36.882301,"median":-12.494338,"eighty":-4.660553,"marketCap":2217693481},{"date":"2021-09-10","current":-14.924552,"twenty":-36.846027,"median":-12.621831,"eighty":-4.667562,"marketCap":2230041440},{"date":"2021-09-17","current":-15.717883,"twenty":-36.782546,"median":-12.868443,"eighty":-4.677957,"marketCap":2348581849},{"date":"2021-09-24","current":-15.569401,"twenty":-36.691859,"median":-13.157303,"eighty":-4.681834,"marketCap":2326395490},{"date":"2021-10-01","current":-15.40482,"twenty":-36.601172,"median":-13.348543,"eighty":-4.688228,"marketCap":2301803571},{"date":"2021-10-08","current":-14.038794,"twenty":-36.419799,"median":-13.514284,"eighty":-4.698005,"marketCap":2097690648},{"date":"2021-10-15","current":-13.791922,"twenty":-36.211219,"median":-13.704912,"eighty":-4.711905,"marketCap":2060802770},{"date":"2021-10-22","current":-14.302124,"twenty":-36.147739,"median":-13.742548,"eighty":-4.712707,"marketCap":2137037717},{"date":"2021-10-29","current":-14.894617,"twenty":-36.057052,"median":-13.751389,"eighty":-4.712707,"marketCap":2225568624},{"date":"2021-11-05","current":-17.34688,"twenty":-35.93009,"median":-13.769271,"eighty":-4.713491,"marketCap":2591988209},{"date":"2021-11-12","current":-14.705813,"twenty":-35.748717,"median":-13.818033,"eighty":-4.717804,"marketCap":2722325377},{"date":"2021-11-19","current":-11.287756,"twenty":-35.549206,"median":-13.791922,"eighty":-4.722509,"marketCap":2089578106},{"date":"2021-11-26","current":-10.567261,"twenty":-35.277146,"median":-13.769271,"eighty":-4.724737,"marketCap":1956200780},{"date":"2021-12-03","current":-9.633286,"twenty":-34.733025,"median":-13.743772,"eighty":-4.733647,"marketCap":1783304246},{"date":"2021-12-10","current":-10.593946,"twenty":-34.69675,"median":-13.726089,"eighty":-4.736536,"marketCap":1961140681},{"date":"2021-12-17","current":-9.900136,"twenty":-34.542583,"median":-13.559686,"eighty":-4.748091,"marketCap":1832703256},{"date":"2021-12-23","current":-10.727371,"twenty":-34.506308,"median":-13.501535,"eighty":-4.748091,"marketCap":1985840185},{"date":"2021-12-31","current":-10.674001,"twenty":-34.279592,"median":-13.259298,"eighty":-4.755923,"marketCap":1975960384},{"date":"2022-01-07","current":-10.433836,"twenty":-34.052875,"median":-13.148429,"eighty":-4.789337,"marketCap":1931501275},{"date":"2022-01-14","current":-10.407151,"twenty":-33.962188,"median":-12.861774,"eighty":-4.806529,"marketCap":1926561374},{"date":"2022-01-21","current":-9.833423,"twenty":-33.925914,"median":-12.627195,"eighty":-4.818217,"marketCap":1820353503},{"date":"2022-01-28","current":-10.980878,"twenty":-33.80802,"median":-12.615247,"eighty":-4.822429,"marketCap":2032769245},{"date":"2022-02-04","current":-9.553231,"twenty":-33.635716,"median":-12.290349,"eighty":-4.840572,"marketCap":1768484543},{"date":"2022-02-11","current":-10.340438,"twenty":-33.454342,"median":-12.150106,"eighty":-4.845027,"marketCap":1914211622},{"date":"2022-02-18","current":-10.500548,"twenty":-33.418067,"median":-11.856872,"eighty":-4.845027,"marketCap":1943851027},{"date":"2022-02-25","current":-11.060933,"twenty":-33.363655,"median":-11.678381,"eighty":-4.852639,"marketCap":2047588947},{"date":"2022-03-04","current":-9.886793,"twenty":-33.218557,"median":-11.471801,"eighty":-4.861046,"marketCap":1830233305},{"date":"2022-03-11","current":-11.36307,"twenty":-33.118801,"median":-11.287756,"eighty":-4.879479,"marketCap":2062408650},{"date":"2022-03-18","current":-12.236255,"twenty":-32.964634,"median":-11.403896,"eighty":-4.892493,"marketCap":2220892530},{"date":"2022-03-25","current":-12.045702,"twenty":-32.873947,"median":-11.63524,"eighty":-4.894098,"marketCap":2186306885},{"date":"2022-04-01","current":-11.351543,"twenty":-32.846741,"median":-11.637614,"eighty":-4.904929,"marketCap":2060316318},{"date":"2022-04-08","current":-10.711827,"twenty":-32.774192,"median":-11.444721,"eighty":-4.923325,"marketCap":1944207365},{"date":"2022-04-14","current":-11.052101,"twenty":-32.701642,"median":-11.36307,"eighty":-4.930814,"marketCap":2005967447},{"date":"2022-04-22","current":-10.221833,"twenty":-32.64723,"median":-11.314441,"eighty":-4.930814,"marketCap":1855272848},{"date":"2022-04-29","current":-8.942402,"twenty":-32.629093,"median":-11.274414,"eighty":-4.936596,"marketCap":1623054941},{"date":"2022-05-06","current":-8.514823,"twenty":-32.384239,"median":-11.218239,"eighty":-4.948211,"marketCap":1545448975},{"date":"2022-05-13","current":-9.315213,"twenty":-31.89453,"median":-11.207701,"eighty":-4.964312,"marketCap":1461249456},{"date":"2022-05-20","current":-9.283689,"twenty":-31.123693,"median":-11.072518,"eighty":-4.983046,"marketCap":1456304449},{"date":"2022-05-27","current":-9.457069,"twenty":-29.84501,"median":-11.052101,"eighty":-4.986838,"marketCap":1483501986},{"date":"2022-06-03","current":-9.267927,"twenty":-29.09231,"median":-10.995642,"eighty":-4.989821,"marketCap":1453831946},{"date":"2022-06-10","current":-9.063024,"twenty":-29.010691,"median":-10.972428,"eighty":-4.991529,"marketCap":1421689403},{"date":"2022-06-17","current":-7.675987,"twenty":-28.892799,"median":-10.957893,"eighty":-5.003334,"marketCap":1204109111},{"date":"2022-06-24","current":-8.479838,"twenty":-28.566326,"median":-10.914166,"eighty":-5.023235,"marketCap":1330206780},{"date":"2022-07-01","current":-8.148841,"twenty":-28.520983,"median":-10.854743,"eighty":-5.025672,"marketCap":1278284211},{"date":"2022-07-08","current":-8.148841,"twenty":-28.194511,"median":-10.83411,"eighty":-5.050454,"marketCap":1278284211},{"date":"2022-07-15","current":-8.05427,"twenty":-28.112893,"median":-10.807426,"eighty":-5.056649,"marketCap":1263449191},{"date":"2022-07-22","current":-8.401029,"twenty":-28.076618,"median":-10.780741,"eighty":-5.064054,"marketCap":1317844264},{"date":"2022-07-29","current":-9.756542,"twenty":-27.958725,"median":-10.754056,"eighty":-5.067411,"marketCap":1530479548},{"date":"2022-08-05","current":-10.607679,"twenty":-27.895245,"median":-10.734042,"eighty":-5.067787,"marketCap":1663994727},{"date":"2022-08-12","current":-131.740049,"twenty":-28.112893,"median":-10.754056,"eighty":-5.098703,"marketCap":1829605794},{"date":"2022-08-19","current":-125.322401,"twenty":-28.983486,"median":-10.773506,"eighty":-5.128046,"marketCap":1740477501},{"date":"2022-08-26","current":-121.222237,"twenty":-31.731294,"median":-10.792616,"eighty":-5.144871,"marketCap":1683534425},{"date":"2022-09-02","current":-115.874197,"twenty":-32.665367,"median":-10.814097,"eighty":-5.147726,"marketCap":1609260848},{"date":"2022-09-09","current":-125.144133,"twenty":-32.873947,"median":-10.847695,"eighty":-5.153385,"marketCap":1738001715},{"date":"2022-09-16","current":-117.122073,"twenty":-33.363655,"median":-10.900823,"eighty":-5.157157,"marketCap":1626591349},{"date":"2022-09-23","current":-109.634817,"twenty":-33.835226,"median":-10.956043,"eighty":-5.162374,"marketCap":1522608340},{"date":"2022-09-30","current":-103.930241,"twenty":-34.370278,"median":-10.970436,"eighty":-5.165852,"marketCap":1443383191},{"date":"2022-10-07","current":-109.456549,"twenty":-35.005085,"median":-10.98826,"eighty":-5.169401,"marketCap":1520132554},{"date":"2022-10-14","current":-108.743477,"twenty":-36.038915,"median":-11.052101,"eighty":-5.181198,"marketCap":1510229411},{"date":"2022-10-21","current":-119.083021,"twenty":-36.583035,"median":-11.072518,"eighty":-5.187486,"marketCap":1653824994},{"date":"2022-10-28","current":-124.074525,"twenty":-36.882301,"median":-11.207701,"eighty":-5.195591,"marketCap":1723147000},{"date":"2022-11-04","current":-121.222237,"twenty":-37.172499,"median":-11.218239,"eighty":-5.20166,"marketCap":1683534425},{"date":"2022-11-11","current":350.616187,"twenty":-37.172499,"median":-11.207701,"eighty":-5.181198,"marketCap":1491871877},{"date":"2022-11-18","current":379.592732,"twenty":-37.045537,"median":-11.13017,"eighty":-5.157157,"marketCap":1615167074},{"date":"2022-11-25","current":398.717251,"twenty":-36.991125,"median":-11.063322,"eighty":-5.13916,"marketCap":1696541903},{"date":"2022-12-02","current":398.13772,"twenty":-36.909507,"median":-11.024004,"eighty":-5.066658,"marketCap":1694075999},{"date":"2022-12-09","current":387.126633,"twenty":-36.89137,"median":-10.97765,"eighty":-5.02421,"marketCap":1647223825},{"date":"2022-12-16","current":360.468212,"twenty":-36.846027,"median":-10.967536,"eighty":-4.986838,"marketCap":1533792244},{"date":"2022-12-23","current":355.831965,"twenty":-36.782546,"median":-10.934179,"eighty":-4.936596,"marketCap":1514065013},{"date":"2022-12-30","current":366.263521,"twenty":-36.709997,"median":-10.881186,"eighty":-4.915836,"marketCap":1558451283},{"date":"2023-01-06","current":388.285695,"twenty":-36.637447,"median":-10.847695,"eighty":-4.890286,"marketCap":1652155633},{"date":"2023-01-13","current":414.944116,"twenty":-36.54676,"median":-10.807426,"eighty":-4.845027,"marketCap":1765587213},{"date":"2023-01-20","current":393.501473,"twenty":-36.292838,"median":-10.792616,"eighty":-4.818217,"marketCap":1674348768},{"date":"2023-01-27","current":409.148807,"twenty":-36.193082,"median":-10.773506,"eighty":-4.748091,"marketCap":1740928174},{"date":"2023-02-03","current":424.796141,"twenty":-36.111464,"median":-10.754056,"eighty":-4.722509,"marketCap":1807507580},{"date":"2023-02-10","current":406.830683,"twenty":-36.020777,"median":-10.719599,"eighty":-4.712707,"marketCap":1731064558},{"date":"2023-02-17","current":429.432388,"twenty":-35.857541,"median":-10.674001,"eighty":-4.685711,"marketCap":1827234812},{"date":"2023-02-24","current":417.84177,"twenty":-35.712442,"median":-10.670994,"eighty":-4.660553,"marketCap":1777916733},{"date":"2023-03-03","current":424.796141,"twenty":-35.503863,"median":-10.614155,"eighty":-4.639212,"marketCap":1807507580},{"date":"2023-03-10","current":372.638361,"twenty":-35.005085,"median":-10.607288,"eighty":-4.615999,"marketCap":1585576226},{"date":"2023-03-17","current":41.372348,"twenty":-34.733025,"median":-10.560589,"eighty":-4.591393,"marketCap":1609591190},{"date":"2023-03-24","current":41.372348,"twenty":-34.624201,"median":-10.540576,"eighty":-4.573709,"marketCap":1609591190},{"date":"2023-03-31","current":42.95386,"twenty":-34.524446,"median":-10.507219,"eighty":-4.555439,"marketCap":1671119906},{"date":"2023-04-06","current":39.790836,"twenty":-34.415622,"median":-10.493877,"eighty":-4.544301,"marketCap":1548062475},{"date":"2023-04-14","current":41.68865,"twenty":-34.188905,"median":-10.460521,"eighty":-4.531449,"marketCap":1621896933},{"date":"2023-04-21","current":40.549962,"twenty":-34.0166,"median":-10.426187,"eighty":-4.504204,"marketCap":1577596259},{"date":"2023-04-28","current":39.771472,"twenty":-33.944051,"median":-10.407151,"eighty":-4.481928,"marketCap":1547309129},{"date":"2023-05-05","current":38.251543,"twenty":-33.862433,"median":-10.373794,"eighty":-4.455479,"marketCap":1488176296},{"date":"2023-05-11","current":28.565693,"twenty":-33.744539,"median":-10.324321,"eighty":-4.434595,"marketCap":1599050357},{"date":"2023-05-19","current":29.849656,"twenty":-33.563166,"median":-10.287068,"eighty":-4.422694,"marketCap":1670924035},{"date":"2023-05-26","current":28.882509,"twenty":-33.418067,"median":-10.241108,"eighty":-4.383956,"marketCap":1616785111},{"date":"2023-06-02","current":27.915363,"twenty":-33.418067,"median":-10.186999,"eighty":-4.350191,"marketCap":1562646188},{"date":"2023-06-09","current":31.168492,"twenty":-33.327381,"median":-10.180328,"eighty":-4.288128,"marketCap":1744749839},{"date":"2023-06-16","current":31.608104,"twenty":-33.146007,"median":-10.106206,"eighty":-4.259562,"marketCap":1769358440},{"date":"2023-06-23","current":29.981539,"twenty":-33.109733,"median":-10.046903,"eighty":-4.243148,"marketCap":1678306615},{"date":"2023-06-30","current":29.497966,"twenty":-32.964634,"median":-10.000205,"eighty":-4.218713,"marketCap":1651237153},{"date":"2023-07-07","current":28.926471,"twenty":-32.873947,"median":-9.964147,"eighty":-4.1658,"marketCap":1619245972},{"date":"2023-07-14","current":30.553035,"twenty":-32.85581,"median":-9.926821,"eighty":-4.090549,"marketCap":1710297797},{"date":"2023-07-21","current":30.553035,"twenty":-32.792329,"median":-9.876834,"eighty":-4.047547,"marketCap":1710297797},{"date":"2023-07-28","current":29.497966,"twenty":-32.701642,"median":-9.846766,"eighty":-3.887913,"marketCap":1651237153},{"date":"2023-08-04","current":30.069462,"twenty":-32.64723,"median":-9.78164,"eighty":-3.815553,"marketCap":1683228335},{"date":"2023-08-11","current":30.34645,"twenty":-32.629093,"median":-9.753368,"eighty":-3.679873,"marketCap":1637646163},{"date":"2023-08-18","current":29.525042,"twenty":-32.384239,"median":-9.623986,"eighty":-3.498851,"marketCap":1593318899},{"date":"2023-08-25","current":29.159972,"twenty":-31.89453,"median":-9.526546,"eighty":-3.248918,"marketCap":1573617892},{"date":"2023-09-01","current":30.620252,"twenty":-31.123693,"median":-9.457069,"eighty":-2.815292,"marketCap":1652421918},{"date":"2023-09-08","current":30.574619,"twenty":-30.089864,"median":-9.425546,"eighty":21.672884,"marketCap":1649959292},{"date":"2023-09-15","current":29.844478,"twenty":-29.355301,"median":-9.394022,"eighty":28.136261,"marketCap":1610557279},{"date":"2023-09-22","current":28.566733,"twenty":-29.037897,"median":-9.384912,"eighty":28.566733,"marketCap":1541603757},{"date":"2023-09-29","current":28.566733,"twenty":-28.983486,"median":-9.362498,"eighty":28.566733,"marketCap":1541603757},{"date":"2023-10-06","current":27.790959,"twenty":-28.647944,"median":-9.334047,"eighty":28.565901,"marketCap":1499739118},{"date":"2023-10-13","current":27.380255,"twenty":-28.530052,"median":-9.283689,"eighty":28.493511,"marketCap":1477575486},{"date":"2023-10-20","current":26.878284,"twenty":-28.194511,"median":-9.183604,"eighty":28.475466,"marketCap":1450486602},{"date":"2023-10-27","current":25.600539,"twenty":-28.112893,"median":-9.130417,"eighty":28.466339,"marketCap":1381533079},{"date":"2023-11-03","current":27.836593,"twenty":-28.103824,"median":-9.063024,"eighty":28.411578,"marketCap":1502201744},{"date":"2023-11-10","current":17.45794,"twenty":-28.040343,"median":-8.963309,"eighty":28.411578,"marketCap":1143966434},{"date":"2023-11-17","current":19.34829,"twenty":-27.92245,"median":-8.858121,"eighty":28.333054,"marketCap":1267835411},{"date":"2023-11-24","current":21.979954,"twenty":-27.886176,"median":-8.814545,"eighty":28.311014,"marketCap":1440280457},{"date":"2023-12-01","current":21.535166,"twenty":-27.840832,"median":-8.716653,"eighty":28.292931,"marketCap":1411134816},{"date":"2023-12-08","current":22.01702,"twenty":-27.138033,"median":-8.653218,"eighty":28.247297,"marketCap":1442709261},{"date":"2023-12-15","current":23.722042,"twenty":-22.45516,"median":-8.520974,"eighty":28.17913,"marketCap":1554434220},{"date":"2023-12-22","current":23.536713,"twenty":-22.327573,"median":-8.511362,"eighty":28.125544,"marketCap":1542290203},{"date":"2023-12-29","current":23.499647,"twenty":-21.891944,"median":-8.440434,"eighty":28.116455,"marketCap":1539861399},{"date":"2024-01-05","current":23.091925,"twenty":-21.601525,"median":-8.401029,"eighty":28.101269,"marketCap":1513144561},{"date":"2024-01-12","current":23.054859,"twenty":-21.536836,"median":-8.274935,"eighty":28.064762,"marketCap":1510715758},{"date":"2024-01-19","current":23.054859,"twenty":-21.278079,"median":-8.148841,"eighty":28.064762,"marketCap":1510715758},{"date":"2024-01-26","current":24.055633,"twenty":-21.102747,"median":-8.05427,"eighty":27.915363,"marketCap":1576293452},{"date":"2024-02-02","current":24.796947,"twenty":-21.093253,"median":-7.928176,"eighty":27.836593,"marketCap":1624869521},{"date":"2024-02-09","current":25.130538,"twenty":-21.031976,"median":-7.865129,"eighty":27.836593,"marketCap":1646728752},{"date":"2024-02-16","current":25.945983,"twenty":-21.031976,"median":-7.802081,"eighty":27.836593,"marketCap":1700162429},{"date":"2024-02-23","current":24.315093,"twenty":-21.007068,"median":-7.723273,"eighty":27.800086,"marketCap":1593295076},{"date":"2024-03-01","current":23.796173,"twenty":-20.989565,"median":-7.61294,"eighty":27.741719,"marketCap":1559291827},{"date":"2024-03-08","current":29.74221,"twenty":-20.957064,"median":-7.505372,"eighty":27.741719,"marketCap":1508286954},{"date":"2024-03-15","current":25.157918,"twenty":-20.935153,"median":-7.407022,"eighty":27.705635,"marketCap":1275808360},{"date":"2024-03-22","current":26.200243,"twenty":-20.913049,"median":-7.206141,"eighty":27.663185,"marketCap":1328666710},{"date":"2024-03-28","current":27.242567,"twenty":-20.839118,"median":-6.902994,"eighty":27.599297,"marketCap":1381525061},{"date":"2024-04-05","current":27.479459,"twenty":-20.773521,"median":-6.720375,"eighty":27.672312,"marketCap":1393538322},{"date":"2024-04-12","current":27.195189,"twenty":-20.752261,"median":-6.581585,"eighty":27.672312,"marketCap":1379122408},{"date":"2024-04-19","current":24.731513,"twenty":-20.592211,"median":-6.530452,"eighty":27.63458,"marketCap":1254184490},{"date":"2024-04-26","current":24.305108,"twenty":-20.463504,"median":-6.424117,"eighty":27.593167,"marketCap":1232560619},{"date":"2024-05-03","current":52.145972,"twenty":-20.446363,"median":-6.384356,"eighty":27.593167,"marketCap":1177299617},{"date":"2024-05-10","current":48.132619,"twenty":-20.446363,"median":-6.342278,"eighty":27.743137,"marketCap":1086690137},{"date":"2024-05-17","current":50.049405,"twenty":-20.444936,"median":-6.28209,"eighty":27.836593,"marketCap":1129965408},{"date":"2024-05-24","current":47.49369,"twenty":-20.43155,"median":-6.201738,"eighty":28.064762,"marketCap":1072265047},{"date":"2024-05-31","current":50.368869,"twenty":-20.413458,"median":-6.176736,"eighty":28.157696,"marketCap":1137177953},{"date":"2024-06-07","current":50.794821,"twenty":-20.371592,"median":-6.052067,"eighty":28.303781,"marketCap":1146794680},{"date":"2024-06-14","current":48.771547,"twenty":-20.317291,"median":-6.025049,"eighty":28.466339,"marketCap":1101115227},{"date":"2024-06-21","current":47.387202,"twenty":-20.263065,"median":-5.998031,"eighty":28.566733,"marketCap":1069860865},{"date":"2024-06-28","current":46.322321,"twenty":-20.208789,"median":-5.9899,"eighty":28.566733,"marketCap":1045819048},{"date":"2024-07-05","current":44.937976,"twenty":-20.108001,"median":-5.945261,"eighty":28.702455,"marketCap":1014564685},{"date":"2024-07-12","current":46.535297,"twenty":-20.013695,"median":-5.909548,"eighty":28.917679,"marketCap":1050627411},{"date":"2024-07-15","current":48.026131,"twenty":-19.996885,"median":-5.902243,"eighty":29.031977,"marketCap":1084285955},{"date":"2024-08-02","current":-82.921226,"twenty":-19.996885,"median":-5.902243,"eighty":29.031977,"marketCap":1120348681},{"date":"2024-08-09","current":-74.302149,"twenty":-20.208789,"median":-5.902243,"eighty":29.031977,"marketCap":1003896329},{"date":"2024-08-16","current":-76.225263,"twenty":-20.445412,"median":-5.902243,"eighty":29.031977,"marketCap":1029879528},{"date":"2024-08-23","current":-76.57492,"twenty":-20.755039,"median":-5.902243,"eighty":29.031977,"marketCap":1034603746},{"date":"2024-08-30","current":-74.302149,"twenty":-20.995203,"median":-5.902243,"eighty":29.031977,"marketCap":1003896329},{"date":"2024-09-06","current":-65.385891,"twenty":-21.204149,"median":-5.902243,"eighty":29.031977,"marketCap":883428769},{"date":"2024-09-13","current":-62.238976,"twenty":-27.868038,"median":-5.902243,"eighty":29.031977,"marketCap":840910807},{"date":"2024-09-20","current":-67.134177,"twenty":-28.357747,"median":-5.902243,"eighty":29.031977,"marketCap":907049859},{"date":"2024-09-27","current":-62.588633,"twenty":-29.84501,"median":-5.902243,"eighty":29.031977,"marketCap":845635025},{"date":"2024-10-04","current":-58.217919,"twenty":-32.64723,"median":-5.902243,"eighty":29.031977,"marketCap":786582300},{"date":"2024-10-11","current":-55.071004,"twenty":-33.009977,"median":-5.902243,"eighty":29.031977,"marketCap":744064338},{"date":"2024-10-18","current":-59.26689,"twenty":-33.526891,"median":-5.902243,"eighty":29.031977,"marketCap":800754954},{"date":"2024-10-25","current":-55.945147,"twenty":-34.188905,"median":-5.902243,"eighty":29.031977,"marketCap":755874883},{"date":"2024-10-31","current":-23.106363,"twenty":-34.660476,"median":-5.902243,"eighty":29.031977,"marketCap":926726893},{"date":"2024-11-08","current":-29.159415,"twenty":-34.69675,"median":-5.894938,"eighty":29.067146,"marketCap":1169496659},{"date":"2024-11-15","current":-29.683237,"twenty":-34.69675,"median":-5.938362,"eighty":29.067146,"marketCap":1190505581},{"date":"2024-11-22","current":-30.556273,"twenty":-34.69675,"median":-6.014779,"eighty":29.067146,"marketCap":1225520451},{"date":"2024-11-29","current":-34.80505,"twenty":-34.733025,"median":-6.162127,"eighty":29.067146,"marketCap":1395926152},{"date":"2024-12-06","current":-33.524597,"twenty":-34.790645,"median":-6.28209,"eighty":29.067146,"marketCap":1344571009},{"date":"2024-12-13","current":-30.148856,"twenty":-34.790645,"median":-6.369746,"eighty":29.067146,"marketCap":1209180179},{"date":"2024-12-20","current":-28.519188,"twenty":-34.790645,"median":-6.515842,"eighty":29.067146,"marketCap":1143819088},{"date":"2024-12-27","current":-28.460986,"twenty":-34.790645,"median":-6.640023,"eighty":29.067146,"marketCap":1141484763},{"date":"2025-01-03","current":-28.169974,"twenty":-34.790645,"median":-6.902994,"eighty":29.067146,"marketCap":1129813140},{"date":"2025-01-10","current":-26.191091,"twenty":-34.80505,"median":-7.407022,"eighty":29.102315,"marketCap":1050446101},{"date":"2025-01-17","current":-26.947723,"twenty":-34.80505,"median":-7.61294,"eighty":29.102315,"marketCap":1080792322},{"date":"2025-01-24","current":-31.254702,"twenty":-34.80505,"median":-7.770558,"eighty":29.102315,"marketCap":1253532347},{"date":"2025-01-31","current":-30.789083,"twenty":-34.80505,"median":-7.928176,"eighty":29.102315,"marketCap":1234857750},{"date":"2025-02-07","current":-29.799642,"twenty":-34.80505,"median":-8.148841,"eighty":29.102315,"marketCap":1195174231},{"date":"2025-02-14","current":-28.984725,"twenty":-34.80505,"median":-8.401029,"eighty":29.102315,"marketCap":1162490373},{"date":"2025-02-21","current":-26.962535,"twenty":-34.80505,"median":-8.511362,"eighty":29.102315,"marketCap":1081386393},{"date":"2025-02-28","current":-24.378625,"twenty":-34.80505,"median":-8.684741,"eighty":29.102315,"marketCap":977753530},{"date":"2025-03-07","current":-38.979965,"twenty":-35.458519,"median":-8.842359,"eighty":29.10472,"marketCap":1116970885},{"date":"2025-03-14","current":-36.302553,"twenty":-36.193082,"median":-9.047263,"eighty":29.10472,"marketCap":1040249653},{"date":"2025-03-21","current":-37.798754,"twenty":-36.737515,"median":-9.244284,"eighty":29.10472,"marketCap":1083123283},{"date":"2025-03-28","current":-36.617542,"twenty":-36.909507,"median":-9.341928,"eighty":29.10472,"marketCap":1049275680},{"date":"2025-04-04","current":-31.656456,"twenty":-36.909507,"median":-9.392793,"eighty":29.10472,"marketCap":907115749},{"date":"2025-04-11","current":-27.876581,"twenty":-36.909507,"median":-9.457069,"eighty":29.102315,"marketCap":798803421},{"date":"2025-04-17","current":-26.69537,"twenty":-36.909507,"median":-9.553231,"eighty":29.102315,"marketCap":764955818}],"updateTime":1745274704001}}}